COIOSDeep risk insights through multi-disciplinary research across the globe
Item refines Peer-reviewed Added

GLP-1 receptor agonists and lung cancer in type 2 diabetes with pulmonary nodules

GLP-1 receptor agonists were linked to fewer lung cancers than metformin, but genetic and SGLT2 inhibitor comparisons gave no support.

This target trial emulation compared adults with type 2 diabetes and a pulmonary nodule starting GLP-1 receptor agonists or metformin. Among 12,622 matched pairs, lung cancer incidence was 1.60% with GLP-1 receptor agonists. With metformin it was 2.14% (HR 0.77, 95% CI 0.64-0.92). The hazard ratio was 0.77 (0.54-1.09) at a 365-day landmark and 0.85 (0.69-1.05) against SGLT2 inhibitors. Cis-Mendelian randomisation, using gene variants that alter GLP1R expression, found no link with lung cancer. The design is observational and open to residual confounding, and outcomes cover only days 90 to 1,095 after starting treatment.

Why it is interesting: The study pairs a trial emulation with genetic evidence to test an observational drug–cancer signal. Neither the SGLT2 inhibitor comparison nor the genetic analysis supported the lower lung cancer incidence seen against metformin.

Source
Cancer Epidemiology, Biomarkers & Prevention, 13 November 2026
Paper
Glucagon-like peptide-1 receptor agonists and lung cancer risk in patients with type 2 diabetes and pulmonary nodules
Authors
Yang TL, Jhou HJ, Chang WC, Chen HY, Chen PH, Lee CH
DOI
10.1158/1055-9965.epi-26-0970
Type
Peer-reviewed article
Design
Target trial emulation in the TriNetX federated network, 12,622 propensity-matched pairs (51 covariates) of new GLP-1RA vs metformin users with type 2 diabetes and a coded pulmonary nodule, outcomes day 90-1,095, with active comparators (DPP-4, SGLT2), landmark analyses, negative controls and drug-target cis-Mendelian randomisation in three GWAS consortia
Verdict
Refines prior evidence
Driver
Cancer
Driver
Obesity, diabetes and GLP-1
Driver
What linked data reveals

Other drivers in Health today